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Tumor necrosis factor-α (TNF), which is an immuno-modulatory cytokine, has been suggested to cause
inﬂammatory responses as well as protection against tissue dysfunction by binding two types of TNF
receptor (TNFR1/TNFR2). However, the physiological effects of TNFR2-speciﬁc activation remain unclear.
We therefore aimed to generate a TNF mutant with full TNFR2-selective agonist activity as a functional
analytical tool. In this study, we utilized a phage display technique to create mouse TNFR2 (mTNFR2)-
selective TNF mutants that bind speciﬁcally to mTNFR2 and show full bioactivity compared with wild-
type TNF. A new phage library displaying TNF mutants was created, in which nine amino acid residues at
the predicted receptor-binding site were randomized. From this library, an agonistic TNF mutant ex-
hibiting high binding selectivity and bioactivity to mTNFR2 was isolated. We propose that this TNF
mutant would be a powerful tool with which to elucidate the functional roles of mTNFR2.
& 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
TNF, a major inﬂammatory cytokine, interacts with two re-
ceptors: TNF receptor type I (TNFR1, also known as TNFRSF1A or
P55) and TNF receptor type II (TNFR2, also known as TNFRSF1B or
P75), resulting in stimulation of host immune defense and in-
ﬂammation [1,2]. These receptors are expressed on different cell
types and transmit cellular signals by their respective distinct
pathways. Unlike TNFR1, which is pan-expressed in most tissues,
TNFR2 is expressed in a more limited manner, restricted primarily
to cells of the immune system such as CD4þ or CD8þ T cells and
several other cell types such as oligodendrocytes and endothelial
cells [3–5]. TNFR1 appears to be the mediator of well-known TNF
signaling effects such as cytotoxicity [6,7] and cytokine secre-
tion [8], whereas in the lymphoid system TNFR2 seems to play aan open access article under the C
aceutical Research, National
ion, 7-6-8 Saito-Asagi, Osaka
da).major role in the activation of T cells [7,9]. Recent reports suggest
that TNFR2 signaling also mediates myocardial protection [10,11],
neuroprotection [12,13] and the activity of regulatory T cells
(Tregs) [14,15]. Although the two TNFRs have been shown to have
distinct functions in some cells, some researchers have suggested
that TNFR2 induces intensive crosstalk with TNFR1 by sharing
some adaptor molecules such as TRAF2 [16]. TNFR2 has another
shared characteristic with TNFR1, as they both utilize analogous
“ligand passing” mechanisms [17]. Analyses of single receptor
knockout (KO) mice and KO cells necessarily failed to reveal mo-
lecular crosstalk between TNFR1 and TNFR2. Interpretations of the
physiological signiﬁcance of TNFR2 signaling in the presence of
both receptors, therefore, require further investigation.
In order to understand TNFR2 signaling, several attempts were
made in the past to create TNFR2-selective TNF mutants. Some
researchers created TNF mutants by conventional site-directed
mutagenesis methods (such as Kunkel's method). These attempts
were not very successful in yielding the desired TNF mutant
(s) having high receptor speciﬁcity and full bioactivity. For ex-
ample, the human TNFR2 (hTNFR2) binding afﬁnity of the double
mutant D143N-A145R was 5–10 fold less than that of wild-typeC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Amino acid sequences of eight clones picked randomly from a phage library displaying TNF mutants.
Receptor binding domain
29 31 32 33 143 145 146 147 149
mutTNF-Lys (-) L (CTG) R (CGC) R (CGG) A (GCC) D (GAC) A (GCC) E (GAG) S (TCT) Q (CAG)
# 1 A (GCC) F (TTC) G (GGG) W (TGG) T (ACC) V (GTC) N (AAC) S (AGC) N (CTC)
# 2 Y (TAC) G (GGG) G (GGG) R (AGG) T (ACG) P (CCC) N (AAC) D (GAC) L (CTC)
# 3 E (GAG) P (CCC) S (TCG) C (TGC) S (CAC) S (AGC) T (ACC) T (ACC) P (CCC)
# 4 R (AGG) P (CCG) G (GGG) W (TGG) H (CAC) Y (TAC) P (CCG) P (CCG) A (GCG)
# 5 P (CCC) M (ATG) V (GTG) R (AGG) N (AAC) T (ACC) Q(CAG) N (AAC) P (CCC)
# 6 R (AGG) E (GAG) W (TGG) C (TGC) F (TTC) K (AAG) Y (TAC) G (GGG) R (AGG)
# 7 W (TGG) C (TGC) R (AGG) A (GCG) H (CAC) T (ACC) A (GCC) H (CAC) D (GAC)
# 8 S (TCG) Q (CAG) R (CGG) G (GGG) P (CCG) N (AAC) T (ACG) P (CCC) G (GGG)
The corresponding codons are shown in parentheses.
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applied a phage display technique and optimized a competitive
panning method, producing a hTNFR2-selective TNF mutant (R2-
7) having high receptor speciﬁcity and full bioactivity [21]. How-
ever, there are species differences between hTNFR2 and mouse
TNFR2 (mTNFR2), and R2-7 did not bind to mTNFR2. Thus,
mTNFR2-selective TNF mutants are needed to study its efﬁcacy in
an in vivo mouse model. Regarding the mouse TNF mutant
(D142N-A144R), analogous to the human TNF mutant (D143N-
A145R), only cell culture supernatants were evaluated from these
gene-encoded adenovirus vector-transduced cells [22]. Neither
receptor speciﬁcity nor bioactivity have been evaluated using the
relevant recombinant protein. In this study, we created potent
mTNFR2-selective agonistic TNF mutants using a phage display
technique.2. Materials and methods
2.1. Cell culture
L-M cells (a mouse ﬁbroblast cell line) were provided by Mo-
chida Pharmaceutical Co. Ltd. (Tokyo, Japan) and were cultured in
minimum Eagle's medium (Wako Pure Chemical Industries, Osaka,
Japan) supplemented with 1% (v/v) fetal bovine serum (FBS) and a
1% (v/v) antibiotic mixture (penicillin 10,000 units/ml, strepto-
mycin 10 mg/ml, and amphotericin B 25 μg/ml) (Nacalai Tesque,
Kyoto, Japan). According to a previous report, mTNFR2/mFas-pre-
adipocytes (PA) derived from TNFR1/R2 / mice expressing a
chimeric receptor consisting of the extracellular and transmem-
brane domains of mTNFR2, and the intracellular domain of mouse
Fas, were produced [23,24]. These cells were cultured in RPMI
1640 (Sigma-Aldrich Japan, Tokyo, Japan) supplemented with 10%
(v/v) FBS, 5 mg/ml Blasticidin S HCl (Invitrogen, Carlsbad, CA), and a
1% (v/v) antibiotics mixture.
2.2. Construction of a novel phage library displaying TNF mutants
The pCANTAB 5E phagemid vector (GE Healthcare Ltd., UK)
encoding mutTNF-Lys (-) was used as a template for PCR [25]. This
TNF mutant was previously reported to be a fully active, lysine-
deﬁcient human TNF mutant. PCR ampliﬁcation was performed
using primers containing the sequence NNS (which encodes all 20
standard amino acids) at the predicted receptor-binding site (9
amino acid residues; 29, 31–33, 143, 145–147 and 149). The PCR
products were digested with NcoI and NotI and then ligated into
pCANTAB 5E. The resultant phagemid was electroporated into
Escherichia coli (E. coli) strain TG1 (Lucigen, Middleton, WI), whichallows read-through of the amber stop codon. The phage library
displaying TNF mutants on the phage surface, as g3p-fusion pro-
teins, was prepared as described previously [25].
2.3. Panning of the phage display library
The mTNFR2 Fc chimera (R&D Systems, Minneapolis, MN) was
immobilized onto a maxisorp immunotube (Thermo Fisher Sci-
entiﬁc Inc., Waltham, MA) at 2 mg/ml diluted in a 50 mM carbonate
bicarbonate buffer. The phage display library (411012 colony
forming units) was reacted with immobilized antigen for 1 h at RT
in the presence of the free form of the mTNFR1 Fc chimera at 2 mg/
ml (R&D Systems). After binding, the unbound phage was washed
away using phosphate buffered saline (PBS) and PBS containing
0.1% (v/v) Tween 20. Bound phage was eluted with 100 mM trie-
thylamine for 5 min at RT. Eluted phage was neutralized with 1 M
Tris-HCl (pH 8.0) and then used to infect E. coli TG1 in order to
amplify the phage. Infected E. coli were incubated on LB agar/
ampicillin plates overnight at 30 °C. Bacterial colonies were re-
suspended and cultured in 2YT containing 100 mg/ml ampicillin
and 2% (w/v) glucose until the OD600 of the culture medium
reached 0.4. Then, helper phage (1.81011 colony forming units)
were added to the culture media for 30 min at 37 °C. The cells
were collected by centrifugation and resuspended in fresh med-
ium containing 100 mg/ml ampicillin and 50 mg/ml kanamycin.
After overnight growth at 30 °C, cells were removed by cen-
trifugation and 4% (w/v) PEG8000 and 0.5 M NaCl were added to
the supernatant. Phage particles were collected by centrifugation
(11,600g, 2 min) and resuspended in PBS containing 2% (v/v) gly-
cerol. These panning steps were repeated three times.
2.4. Screening of TNFR2-selective agonist candidates from the phage
display library
After the ﬁnal round of panning, the phage mixture was used to
infect E. coli TG1 and plated on LB agar/ampicillin plates. Single
clones were picked randomly from the plate and each colony was
grown in 2YT containing 100 mg/ml ampicillin and 2% (w/v) glu-
cose for 3 h at 37 °C. After incubation, for induction, 1 mM iso-
propyl-beta-D-thiogalactopyranoside (IPTG) was added to each
medium and incubated for 24 h at 30 °C. Supernatants containing
each TNF mutant from each clone were collected and used to
determine their afﬁnities for mTNFR2 and mTNFR1 by capture
ELISA as described previously [21], and their cytotoxicity mediated
via mTNFR2 and mTNFR1 by mTNFR2/mFas-PA and L-M cells cy-
totoxic assay, respectively. We screened clones having signiﬁcant
afﬁnity and cytotoxicity for mTNFR2 but not for mTNFR1. After this
procedure, the phagemid vectors were sequenced using a Big Dye
Fig. 1. Determination of relative afﬁnities and bioactivities of TNF mutants of
mouse TNFRs by ELISA and cytotoxic assays. ELISA assays with an E. coli super-
natant containing a TNF mutant detected against (A) mouse TNFR2 and (B) mouse
TNFR1. In (A) and (B): gray bar, mutTNF-Lys (-) (shown as Lys (-)); hatched bar,
mouse wtTNF (mTNF) as a positive control; white bar, TNF mutants; black bar,
TNFR2-selective binding clones. Afﬁnities of TNFR2-selective clones for TNFR2 were
more than 100% of the mouse wtTNF value, and the afﬁnity for TNFR1 was less than
100% that of wtTNF value. In the cytotoxic assay, selected TNFR2-selective agonistic
clones from TNFR2-selective binding clones were assessed to determine their
bioactivities. (C) TNFR2-mediated bioactivity was measured using mTNFR2/mFas-
PA. (D) TNFR1-mediated bioactivity was measured using L-M cells. In (C) and (D):
gray bar, mutTNF-Lys (-) (shown as Lys (-)); hatched bar, mouse wtTNF; white bar,
TNF mutants; black bar, TNFR2-selective agonist candidates. Each column re-
presents the mean7SEM (n¼3).
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Pleasanton, CA).
2.5. Expression and puriﬁcation of recombinant TNF mutants
The protocol for expression and puriﬁcation of the recombinant
proteins was the same as that described previously [25–27].Brieﬂy, pCANTAB 5E vectors encoding each TNF mutant were sub-
cloned into the expression vector pYas. TNF mutants were pro-
duced in E. coli (BL21λDE3). The inclusion body of each TNF mu-
tant was washed in 2.5% (v/v) triton X-100 and solubilized in 6 M
guanidine-HCl, 0.1 M Tris-HCl (pH 8.0), and 2 mM ethylenedia-
minetetraacetic acid (EDTA). Solubilized protein at 10 mg/ml was
reduced with 10 mg/ml dithiothreitol for 4 h at RT and refolded by
100-fold dilution in a refolding buffer (100 mM Tris–HCl, 2 mM
EDTA, 0.5 M arginine, and 551 mg/L oxidized glutathione, pH 9.5).
After dialysis against 20 mM Tris–HCl (pH 7.4) containing 100 mM
urea, active trimeric proteins were puriﬁed by ion-exchange
chromatography and gel-ﬁltration chromatography.
2.6. Cytotoxicity assays
The mTNFR2/mFas-PA were seeded in 96-well ﬂat bottom
plates (Thermo Fisher Scientiﬁc Inc.) at a density of 1.5104 cells/
well. Serial dilutions of mouse wtTNF and TNF mutants were
prepared with 1 mg/ml cycloheximide and added to each well.
After 48 h incubation, the cell viabilities were analyzed using a
WST-8 assay kit (Nacalai Tesque). L-M cells were cultured in 96-
well ﬂat bottom plates in the presence of serially diluted mouse
wtTNF and TNF mutants, and for 24 h at 3.0104 cells/well. Cy-
totoxicity was then assessed using a methylene blue assay as de-
scribed previously [26]. Experimental data were analyzed using a
logistic regression model to calculate the mean effective con-
centrations (EC50) with GraphPad Prism version 5 (GraphPad
Software, San Diego, CA).
2.7. Surface plasmon resonance (SPR) assay (BiacoreⓇ assay)
The binding kinetics of the mouse wtTNF and TNF mutants
were analyzed by SPR (BIAcore T200; GE Healthcare, UK).
mTNFR1-Fc or mTNFR2-Fc were immobilized separately on a CM5
sensor chip, resulting in an increase of 3000–3500 RU. During the
association phase, wtTNF or TNF mutants diluted in running buffer
(HBS-EP) at 100, 50, 25, 12.5 or 6.25 nM were passed over the
immobilized ligands for 2 min at a ﬂow rate of 20 ml/min. During
the dissociation phase, HBS-EP was run over the sensor chip for
1 min at a ﬂow rate of 20 ml/min. These measurements were per-
formed by single-cycle kinetics. The data were analyzed by global-
ﬁtting using the BIAcore T200 Evaluation Software (GE Healthcare)
applying a 1:1 Langmuir binding model. The obtained sensor-
grams were ﬁtted globally over the range of injected concentra-
tions and simultaneously over the association and dissociation
phases.3. Results and discussion
3.1. Construction of a novel phage library displaying TNF mutants
We designed a phage display library that expressed TNF mu-
tants having 9 amino acid residue replacements (aa 29, 31–33, 143,
145–147, 149) in the predicted receptor-binding site of TNF, as
described previously [26,28]. Although the structures of human
TNF and mouse TNF are very similar [29], we selected a human
TNF mutant named mutTNF-Lys (-) as a template, which drama-
tically improved the in vivo stability due to effects of a novel PE-
Gylation technique [25]. To construct the phage library, PCR was
performed to replace these amino acids randomly with primers
containing NNS sequences. As a result, we conﬁrmed that the
phage display library consisted of 5.0108 independent re-
combinant clones. Amino acid analysis of eight clones picked
randomly from this library revealed that each one was a mutant
containing amino acid substitutions (Table 1).
Table 2
Amino acid sequences of potential TNFR2-selective TNF mutants.
Receptor binding domain
29 31 32 33 142 (143) 144 (145) 145 (146) 146 (147) 148 (149)
mouse TNF L Q R A D A E S Q
mutTNF-Lys (-) L R R A D A E S Q
Clone 7 T H G G N P D S E
Clone 8 T I E T T D D R E
Clone 9 S R G G N N H P Q
Clone 10 A L G P S T E T N
Clone 16 G I G A T S N A E
Amino acid positions of mutTNF-Lys (-) and each clone in the homologous region are shown in parentheses, because human TNF has one more amino acid than mouse TNF.
Fig. 2. In vitro bioactivity assay of TNF mutants via mTNFR2 or TNFR1. The receptor-speciﬁc bioactivity (% viability) was measured following treatment of mTNFR2/mFas-PA
or L-M cells with mouse wtTNF or TNF mutants followed by a cytotoxicity assay, as described in Section 2. (A) TNFR2-mediated bioactivity was measured using mTNFR2/
mFas-PA. (B) TNFR1-mediated bioactivity was measured using L-M cells. In (A) and (B): open circles, mouse wtTNF; closed circles, clone 7; open triangles, clone 8; closed
triangles, clone 9; open squares, clone 10; and closed squares, clone 16. Each point represents the mean7SEM (n¼5).
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phage display library
To enrich for the mTNFR2-binding TNF mutants, three rounds
of panning were performed against mTNFR2 in competition with
mTNFR1-Fc as described in Section 2. The ratios of selected TNF
mutants to applied TNF mutants increased at each round of pan-
ning (data not shown), suggesting that potent binders to mTNFR2
were concentrated from the library. We then screened for clones
that bound speciﬁcally to mTNFR2 but not to mTNFR1. Super-
natants of 26 single clones randomly selected from E. coli were
collected and subjected to screening by capture ELISA. As shown in
Fig. 1, most of the selected clones bound to mTNFR2 (Fig. 1(A)). On
the other hand, almost none of the clones bound to mTNFR1 (Fig. 1
(B)), suggesting a remarkable enrichment of TNFR2-selective
clones through each round of panning. We eventually identiﬁed 13
clones that strongly and selectively bound to TNFR2, compared to
binding of mouse wtTNF (Fig. 1(A) and (B) black bar). Thereafter, to
evaluate the agonistic potency against mTNFR2 and mTNFR1, two
bioassays were performed using mTNFR2/mFas-PA and L-M cells,
which can evaluate mTNFR2 and mTNFR1-mediated cytotoxic ef-
fects, respectively. Six clones (clones 3, 7, 8, 9, 10 and 16) showed
mTNFR2 cytotoxic effects compared with mouse wtTNF (Fig. 1(C)).
However, only clone 3 showed minimal mTNFR1 cytotoxic effects
(Fig. 1(D)). Consequently, we identiﬁed ﬁve candidates (clones 7, 8,
9, 10 and 16) as TNFR2-selective TNF mutants having promising
agonistic activity. Amino acid analysis of these ﬁve clones revealed
that each one had a different protein sequence, and no tendency of
amino acids was observed in the mutated region (Table 2).3.3. Bioactivity of TNFR2-selective recombinant TNF mutants
To examine the bioactivities of these ﬁve candidates in detail,
recombinant proteins were prepared using a general protein ex-
pression system as described previously [25–27]. TNF mutants
expressed as an inclusion body in E. coli (BL21λDE3) were dena-
tured and refolded. Next, active TNF mutants were puriﬁed by ion-
exchange and gel-ﬁltration chromatography. TNF mutant purity
was greater than 90%, as judged by sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis, and all mutants were conﬁrmed to
form homotrimers in the same manner as wtTNF by gel-ﬁltration
analysis (data not shown). Previously, we created a TNFR2-selec-
tive TNF mutant (R2-7) that bound to only human TNFR2 [21].
However, the in vivo function of TNFR2 must be examined using
animals, e.g. in mouse model systems. Therefore, mTNFR2-selec-
tive TNF mutants were generated. To discover these mutant TNFs,
TNFR2-mediated cytotoxic assays were carried out using the
mTNFR2/mFas-PA. Among the candidates, clones 7, 10 and 16
showed dose-dependent cytotoxicity, with EC50 values of 0.48,
1.54 and 1.14 ng/ml, respectively, while the other clones showed
almost no cytotoxicity (Fig. 2(A)). These results demonstrated that
clones 7, 10 and 16 had similar or higher bioactivities compared to
that of mouse wtTNF, because the EC50 value of wtTNF against
mTNFR2/mFas-PA cytotoxicity is 3.01 ng/ml. Moreover, the TNFR1-
mediated cytotoxic assay was performed using L-M cells. None of
the TNF mutants showed cytotoxicity, and their bioactivities were
signiﬁcantly lower than that of mouse wtTNF (Fig. 2(B)). These
observations suggested that clones 7, 10 and 16 had mTNFR2-se-
lective agonistic activity.
Fig. 3. SPR assay of TNF mutants for mTNFR1 and mTNFR2. The receptor-speciﬁc afﬁnity of mouse TNF, human TNF, mutTNF-Lys (-) and each TNF mutant was measured
using BIAcore T200 for mTNFR1 (A) and mTNFR2 (B), respectively. Each protein (100, 50, 25, 12.5 or 6.25 nM) was sequentially injected by the single-cycle kinetics method.
Table 3
Binding kinetics of TNF mutants to mTNFR1 and mTNFR2.
mTNFR1 mTNFR2
kona (105 M1 s1) koffb (104 s1) KDc (109 M) kona (105 M1 s1) koffb (104 s1) KDc (109 M)
mouse TNF 1.66 9.69 5.84 5.37 56.0 10.4
mutTNF-Lys (-) 4.25 19.9 4.68 N.D.
Clone 7 N.D. 33.8 257 7.61
Clone 8 N.D. 538 37,400 69.4
Clone 9 N.D. N.D.
Clone 10 N.D. 8.43 173 20.5
Clone 16 N.D. 9.71 176 18.1
Kinetic parameters for TNFs and TNF mutants were calculated from the respective sensorgrams using the BIAcore T200 Evaluation Software, and taking into consideration
that TNF binds as a trimer.
a kon is the association kinetic constant.
b koff is the dissociation kinetic constant.
c KD is the equilibrium dissociation constant (KD¼ koff/kon).
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To investigate the binding properties of these TNF mutants in
detail, their binding dissociation constants (kinetic on- and off-
rates) for mTNFR2 and mTNFR1, respectively, were determined
using SPR (Fig. 3(A) and (B)). As shown in Table 3, three clones (7,
10 and 16) bound strongly to mTNFR2 with equilibrium dissocia-
tion constants (KD) of 7.61, 20.5 and 18.1 nM, respectively; in
contrast, they bound to mTNFR1 with greatly reduced afﬁnity.
Thus, clone 7 was identiﬁed as the most highly mTNFR2-selective
mutant having full bioactivity. The EC50 values of TNF mutants
against mTNFR2/mFas-PA cytotoxicity (0.48, 1.14 and 1.54 ng/ml)
were correlated with the KD rates against mTNFR2 (7.61109,
18.1109 and 20.5109 M), respectively (Table 3), but this
correlation was not observed for mouse wtTNF (EC50:3.01 ng/ml,
KD:10.4109 M). Interestingly, the SPR sensorgram indicated
that the association and dissociation of wtTNF to mTNFR2 was
slow, whereas that of each mutant was quick (Fig. 3(A)). Further-
more, the maximum binding response (Rmax) of each mutant was
lower than that of wtTNF. Therefore, speciﬁcally focusing on
wtTNF and clone 7, we considered that both proteins show almost
the same afﬁnity and bioactivity towards mTNFR2, but their
modes of binding to mTNFR2 are different.
Our previous report showed that hTNFR2-selective TNF mu-
tants with amino acid substitutions at positions 29, 31 and 32
indeed had identical properties to those of human wtTNF, in which
these three amino acids play critical roles in maintaining the
binding of wtTNF to hTNFR2 [21]. On the other hand, mTNFR2-
selective TNF mutants with amino acid substitutions at the same
positions were randomized, and position 32 was consistently a
Glycine residue. Following this line of reasoning, a species differ-
ence has apparently existed between hTNFR2 and mTNFR2, in
which hTNFR2 selective TNF mutants could not bind to mTNFR2.
However, the reason why this replacement would increase the
selectivity for mTNFR2 is unclear based on results of the present
study. We are currently attempting to determine the three-di-
mensional structure of the mouse TNF-TNFR2 complex by X-ray
crystallography, in order to carry out structure-activity relation-
ship studies in the near future.
We have analyzed human TNFR2 and it signaling. By con-
structing a TNF mutant with human TNFR2-selective agonistic
ability, we previously elucidated the three-dimensional structure
of the TNF–TNFR2 complex, and identiﬁed a new member of the
TNFR2 signaling family [30,31]. In terms of mouse TNFR2, it is
difﬁcult to conﬁrm its function using mouse or a mouse-derived
cell line, because human TNF cannot selectively stimulate mouse
TNFR2. To overcome this species speciﬁcity, we generated a TNF
mutant that has mTNFR2-selective agonist ability. The mutant can
fully activate TNFR2 signaling independently in vitro, and also can
be expected to show a synergistic effect in vivo by TNFR2 clus-
tering with the antibody [32]. Furthermore, researchers have de-
veloped designer TNF mutants to enhance TNF signaling in a
previous study. Such mutants enhance TNF signaling by increasing
ligand stability and clustering among ligand–receptor complexes,
for example, by increasing internal or external crosslinking of
monomeric TNF and oligomerization of trimeric TNF [33–35]. This
approach will be a very effective method of modifying our TNFR2-
selective mutant to enhance TNFR2 signaling. This mutant has the
potential to be a great analytical tool and a promising drug seed.Acknowledgements
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